CLDX Stock News 13.33 05/18/2014 17:51:27 Celldex Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celldex Therapeutics Inc (CLDX) 13.33 $CLDX

This Week in Biotech: Celldex Buddies Up While Isis' Experimental Diabetes Therapy Impresses
Sean Williams, The Motley Fool - Motley Fool - Sat May 17, 12:18PM CDT
With the  SPDR S&P Biotech Index  up  15% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...

This Beaten-Down Stock Is Ready to Rebound
at The Street - Fri May 16, 8:28AM CDT
Consider buying this oversold stock as it gears up for a big move higher.

Celldex Gains on Bristol-Myers Squibb Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 4:20PM CDT
Celldex Therapeutics, Inc. (CLDX) signed a deal with Bristol-Myers for the development of Celldex's varlilumab and Bristol-Myers' nivolumab in a phase I/II study.

Could Bristol-Myers End Up Acquiring Celldex?
Todd Campbell, The Motley Fool - Motley Fool - Thu May 15, 1:30PM CDT
Celldex 's shares jumped by more than a quarter following news that Bristol-Myers has paid Celldex $5 million up front and will pay half of development costs for a new study that teams Bristol's PD-1 drug nivolumab up with Celldex's promising...

Exosomes Common Link in Cancer Drug Development
ACCESSWIRE - Thu May 15, 1:18PM CDT
Whitefish, MT / May 15, 2014 / The cancer drug business is ablaze lately as pharmaceutical companies of all sizes are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are being held in high regard as the next generation of cancer therapies as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465 for patients with advanced melanoma who did not respond to Bristol-Myers Squibb's (NYSE: BMY) Yervoy. Roche is making headlines not just with MK-3465, releasing data ahead of the May 30 start of this year's American Society of Clinical Oncology (ASCO) meeting, showing that its immune therapy drug MPDL3280A shrunk tumors in 10 of 20 bladder cancer patients. Pfizer (NYSE: PFE) is looking to consolidate some of its developmental pipeline through potentially the biggest biotech acquisition in history, offering more than $100 billion to buy AstraZeneca (NYSE: AZN). AstraZeneca's MedImmune unit is partnered with Pfizer, working on development of an anti-CTLA-4 combination therapy. MedImmune expanded its pipeline this week by inking a pact with Incyte (NASDAQ: INCY) to couple its MEDI4736 with Incyte's INCB24360 in a PD-L1-targeting regimen.

36.6% Return Seen to Date on SmarTrend Celldex Therapeutics Call (CLDX)
Comtex SmarTrend(R) - Wed May 14, 4:45PM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 2 months, Celldex Therapeutics has returned 36.56% as of today's recent price of $15.74.

Look for Shares of Celldex Therapeutics to Potentially Pullback after Yesterday's 26.94% Rise
Comtex SmarTrend(R) - Wed May 14, 4:16PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $12.85 to a high of $15.97. Yesterday, the shares gained 26.9%, which took the trading range above the 3-day high of $13.69 on volume of 9.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Why bluebird bio, Celldex Therapeutics, and MannKind Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed May 14, 4:15PM CDT
Despite a slower, but still steady stream of earnings reports, ongoing merger and acquisition rumors in the pharmaceutical sector, and mixed economic data, investors decided today would be the day to push the broad-based S&P 500 lower and lock...

Celldex Therapeutics Announces Varlilumab (CDX-1127) Phase 1 Clinical Data to be Presented at ASCO Annual Meeting 2014
GlobeNewswire - Wed May 14, 4:01PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from its Phase 1 study of varlilumab, a fully human monoclonal antibody targeting CD27, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 in Chicago. The abstracts accepted for poster presentation are listed below. In addition, the data will be discussed during a Poster Highlight Session entitled "Modulating the Anti-tumor Immune Response" by Dr. Cassian Yee of The University of Texas MD Anderson Cancer Center on Monday, June 2, 2014 from 5:15 to 5:30 p.m. CDT.

Exosomes Part and Parcel of Celldex, Pfizer, Incyte and More Cancer Targets
ACCESSWIRE - Wed May 14, 2:50PM CDT
Whitefish, MT / May 14, 2014 / Pharmaceutical companies big and small are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are receiving the praise of analysts as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465. Shares of Celldex Therapeutics (NASDAQ: CLDX) are chugging ahead by 25 percent on Wednesday after striking a deal with Bristol-Myers Squibb (NYSE: BMY) to collaborate on the clinical development of BMY's PD-1 investigational drug nivolumab in combination with Celldex's CD27-targeting drug candidate varlilumab.

Why Celldex Therapeutics Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Wed May 14, 1:30PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Celldex Therapeutics , a clinical-stage...

Celldex, Bristol-Myers Cut Deal on Immuno-Oncology Combo Trial
Ben Fidler, The Motley Fool - Motley Fool - Wed May 14, 11:05AM CDT
Big pharmaceutical companies everywhere are playing the mix and match game to come up with the best possible combination of immunotherapy drugs to treat cancer. Hampton, NJ-based Celldex Therapeutics has become the latest beneficiary of that...

Why Celldex Therapeutics (CLDX) Stock Is Surging Today
at The Street - Wed May 14, 10:43AM CDT
Celldex Therapeutics (CLDX) surged Wednesday after the company announced a clinical trial collaboration with Bristol-Myers Squibb (BMY).

Bristol, Celldex Collaborating on Cancer Immunotherapy Study
at The Street - Wed May 14, 9:39AM CDT
The phase I/II study will combine Bristol's PD-1 checkpoint inhibitor nivolumab with Celldex's CD27-targeted antibody varlilumab, also known as CDX-1127.

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Barbarian At The Gate" Stock
at The Street - Wed May 14, 9:16AM CDT
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab
Business Wire - Wed May 14, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that they have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex's CD27 targeting investigational antibody in a Phase 1/2 study. Multiple tumor types will be explored in the study, which could potentially include non-small cell lung cancer (NSCLC), metastatic melanoma, ovarian, colorectal (CRC) and squamous cell head and neck cancers.

Post Earnings Update: Celldex Therapeutics Has Sunk 12.6% Lower in Past Week (CLDX)
Comtex SmarTrend(R) - Mon May 12, 12:05PM CDT
When Celldex Therapeutics (NASDAQ:CLDX) reported earnings a week ago on May 1st, 2014, analysts, on average, expected the company to report a loss of $0.27 on sales of $337.0 thousand. The company actually reported a loss of $0.33 per share on sales of $416.0 thousand, missing EPS estimates by $0.06 and matching revenue estimates. Shares of Celldex Therapeutics have slipped from $14.64 to $12.79, representing a loss of 12.6%, since the company reported earnings 11 days ago.

Today's Dead Cat Bounce Stock Is Celldex Therapeutics (CLDX)
at The Street - Fri May 09, 9:03AM CDT
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
M2 - Thu May 08, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bjnnz/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Adherex Technologies Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Agonox - AlphaMab Co., Ltd - Amarna Therapeutics B.V. - Amgen Inc. - Aphios Corporation - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Bavarian Nordic A/S - BioMarin Pharmaceutical Inc. - BioNumerik Pharmaceuticals, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell Therapeutics, Inc. - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Curaxys, S.L. - Dainippon Sumitomo Pharma Co., Ltd. - Dompe Farmaceutici S.p.A. - EirGen Pharma Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. and much more... For more information visit http://www.researchandmarkets.com/research/2b...tic_breast

Downtrend Call Working As Celldex Therapeutics Stock Falls 49.5% (CLDX)
Comtex SmarTrend(R) - Wed May 07, 10:59AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 2 months, Celldex Therapeutics has returned 49.46% as of today's recent price of $12.54.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 119

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 82

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 88

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 114

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 185

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 69

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 120

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 125

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading

Top 5 Most Recently Viewed Articles

Preliminary Ratings Issued by KBRA for Upstart Securitization Trust

Updated Category News Views 388

Preliminary Ratings by KBRA for Upstart Securitization Trust 2024-1 KBRA recently assigned preliminary ratings to the three classes of notes issued by Upstart Securitization Trust 2024-1, also known as UPST 2024-1. This securitization involves a notable value of $208.001 million, primarily revolving around unsecured consumer loans. Details of the Ratings The assigned...

Continue Reading
Alchemy Pay Expands With Mississippi License Milestone

Updated Category News Views 247

Alchemy Pay's Latest Regulatory Push Well, here's something to chew on—Alchemy Pay, that stalwart in the fiat-crypto payment arena, just nabbed a Money Transmitter License down in Mississippi. Good move, because this means they've got their hands now in 20 states across the U.S. Quite a feat for a company out of Hong Kong looking to make waves in the regulatory ocean....

Continue Reading
Optimi Health Steps Up with Microdose Psilocybin

Updated Category News Views 27

New Horizons in the World of Psychedelics Optimi Health has just dropped a noteworthy update, and it's not something to ignore if you're keeping an eye on the psychedelic sector. They're rolling out microdose psilocybin products — a move that’s poised to stir the waters in clinical research. With dosages standardized at 1mg and 2mg, Optimi is targeting the need for...

Continue Reading
PowerBank Corporation Sees Stock Surge After Funding News

Updated Category News Views 111

PowerBank Corporation Stock Surge PowerBank Corporation (NASDAQ: SUUN) experienced significant stock gains recently, particularly on Wednesday. This rise came after the company announced an initial payment of $4 million for its solar projects, including Elmira, Jordan Road 1, and Jordan Road 2. This financial boost has attracted investor interest and propelled the stock...

Continue Reading
Lazard's Q3 2026: Surging Revenue, Waning Net Income

Updated Category News Views 88

Breaking Down the Numbers Lazard just dropped its Q3 2026 earnings report, and you can smell both optimism and caution in the air. Sure, $814 million in net revenue isn’t anything to sneeze at, especially when it’s a neat 9% jump from last year’s $748 million. Adjusted figures were a whisker away at $805 million. But dig deeper, and things get a tad less rosy—net...

Continue Reading